EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence.
about
Current Therapeutic Advances Targeting EGFR and EGFRvIII in GlioblastomaCtBP2 overexpression promotes tumor cell proliferation and invasion in gastric cancer and is associated with poor prognosis.Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells.PKG II inhibits EGF/EGFR-induced migration of gastric cancer cellsRegulators of homologous recombination repair as novel targets for cancer treatment.Type II cyclic guanosine monophosphate-dependent protein kinase inhibits epidermal growth factor receptor activation in different cancer cell lines.Regulation of ubiquitination-mediated protein degradation by survival kinases in cancer.Cell targeting with hybrid Qβ virus-like particles displaying epidermal growth factor.Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.A view on EGFR-targeted therapies from the oncogene-addiction perspective.Type II cGMP-dependent protein kinase inhibits epidermal growth factor-induced phosphatidylinositol-3-kinase/Akt signal transduction in gastric cancer cells.Superparamagnetic iron oxide nanoparticles conjugated with epidermal growth factor (SPION-EGF) for targeting brain tumors.Type II cGMP-dependent protein kinase inhibits activation of key members of the RTK family in gastric cancer cells.Translational research of a novel humanized epidermal growth factor receptor-related protein: a putative inhibitor of pan-ErbB.Epidermal growth factor receptor as a therapeutic target in glioblastoma.Pilot study of a novel combination of two therapeutic vaccines in advanced non-small-cell lung cancer patients.Erlotinib: early clinical development in brain cancer.Genomewide RNAi screen identifies protein kinase Cb and new members of mitogen-activated protein kinase pathway as regulators of melanoma cell growth and metastasis.Anticancer drug development from traditional cytotoxic to targeted therapies: evidence of shorter drug research and development time, and shorter drug lag in Japan.
P2860
Q28087306-0A7A38B2-15A2-4DC0-B25F-11D29CEC8302Q33709869-E5E2980A-F740-4710-821E-25ED30B5C95BQ34276149-03CBD12A-F7A7-4AD3-9611-460F299F0F72Q34684803-1D58FA3C-BD39-40BF-8146-4A8D63353B36Q35200273-D1EEE20E-EB12-4542-B146-BB0964C817BAQ35758953-CD66BB86-0210-48F8-94DF-F0B80A9D610FQ35971560-56C0C64A-0B44-41B3-BC6C-DB3EFCA7DDA4Q36136393-29D71584-DE15-4513-B6C7-9ECA41069422Q36297064-510716E1-E9FB-4CCD-B4D6-54B301319A31Q36795486-79F734AE-F6CB-4A2C-9063-C16DA1C6D8E5Q37327723-99EF4B7A-35C0-416D-B644-8CB902CB641BQ37464021-F299AE11-4126-4199-A8DA-47583AE829D1Q37565593-63E8845D-E72F-45B6-995C-65FC487FB24CQ37938692-72C3BF9B-01D3-4E64-BB78-7183306D275FQ38098098-F9F06878-CC3E-40A4-AF37-10CC1D5594A0Q38207923-53F90DC5-2F91-420B-B201-025D6806CB92Q38212394-BD0EDC67-C531-4A14-B6F9-386F07A93174Q39035993-8CF16533-9153-4523-8469-C10CE2850D37Q48005672-DAC94AC0-CB54-4E07-AD76-ACE5941684D4
P2860
EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence.
@en
EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence.
@nl
type
label
EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence.
@en
EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence.
@nl
prefLabel
EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence.
@en
EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence.
@nl
P2093
P356
P1476
EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence
@en
P2093
Angelo Angelo
Anna Elisa Quatrale
Giuseppe Colucci
Letizia Porcelli
Nicola Silvestris
P304
P356
10.2741/3833
P577
2011-01-01T00:00:00Z